Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 5
2013 12
2014 10
2015 5
2016 7
2017 6
2018 4
2019 1
2020 4
2021 6
2022 4
2023 2
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
ARA 290 for treatment of small fiber neuropathy in sarcoidosis.
van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M. van Velzen M, et al. Expert Opin Investig Drugs. 2014 Apr;23(4):541-50. doi: 10.1517/13543784.2014.892072. Epub 2014 Feb 21. Expert Opin Investig Drugs. 2014. PMID: 24555851 Review.
Moreover, ARA 290 treatment resulted in significant increases in corneal nerve fibers, improved sensory pain thresholds, improved quality of life and physical functioning. ...Given the excellent safety profile while reducing neuropathy symptoms, the prospects of …
Moreover, ARA 290 treatment resulted in significant increases in corneal nerve fibers, improved sensory pain thresholds, impro …
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.
Zhang W, Yu G, Zhang M. Zhang W, et al. Peptides. 2016 Feb;76:73-9. doi: 10.1016/j.peptides.2016.01.003. Epub 2016 Jan 13. Peptides. 2016. PMID: 26774587
ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer. ...However, whether other mechanisms or pathways are involved in ARA 290-mediated analgesic effect rema …
ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such a …
Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Al-Onaizi MA, Thériault P, Lecordier S, Prefontaine P, Rivest S, ElAli A. Al-Onaizi MA, et al. Brain Behav Immun. 2022 Jan;99:363-382. doi: 10.1016/j.bbi.2021.07.016. Epub 2021 Jul 31. Brain Behav Immun. 2022. PMID: 34343617
Here, we used a recently identified non-erythropoietic analogue of EPO, ARA 290, to evaluate its therapeutic potential in AD therapy. We first evaluated the effects of early systemic ARA 290 administration on AD-like pathology in an early-onset model, …
Here, we used a recently identified non-erythropoietic analogue of EPO, ARA 290, to evaluate its therapeutic potential in AD t …
Editorial.
Tracey KJ. Tracey KJ. Mol Med. 2013 Nov 8;19(1):333. doi: 10.2119/molmed.2013.00135. Mol Med. 2013. PMID: 24178588 Free PMC article. No abstract available.
A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets.
Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Östenson CG, Kumagai-Braesch M. Watanabe M, et al. Transplantation. 2016 Mar;100(3):554-62. doi: 10.1097/TP.0000000000001026. Transplantation. 2016. PMID: 26683514
We investigated whether ARA 290 protects islets and ameliorates inflammatory responses following PITx thus improving engraftment. ...ARA 290 appears to be a promising candidate for improvement of PITx....
We investigated whether ARA 290 protects islets and ameliorates inflammatory responses following PITx thus improving engraftme …
Synthesis and evaluation of (99m)Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region.
Mohtavinejad N, Hajiramezanali M, Akhlaghi M, Bitarafan-Rajabi A, Gholipour N. Mohtavinejad N, et al. Iran J Basic Med Sci. 2021 Nov;24(11):1488-1499. doi: 10.22038/IJBMS.2021.57565.12799. Iran J Basic Med Sci. 2021. PMID: 35317117 Free PMC article.
Erythropoietin (EPO) has protection effects on ischemic tissue due to nonhematopoietic peptide (pHBSP; ARA-290) which is derived from the B-subunit of EPO. MATERIALS AND METHODS: We designed and synthesized a modified DOTA-(Lys-Dabcyl(6), Phe(7))-ARA-290 …
Erythropoietin (EPO) has protection effects on ischemic tissue due to nonhematopoietic peptide (pHBSP; ARA-290) which is deriv …
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.
Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. Brines M, et al. Mol Med. 2015 Mar 13;20(1):658-66. doi: 10.2119/molmed.2014.00215. Mol Med. 2015. PMID: 25387363 Free PMC article. Clinical Trial.
ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential activity of ARA 290 in type 2 diabetes and painful neuropathy, subjects were enrolled in this phase 2 study. ...
ARA 290 has shown efficacy in preclinical and clinical studies of metabolic control and neuropathy. To evaluate the potential …
ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.
Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. Dahan A, et al. Mol Med. 2013 Nov 8;19(1):334-45. doi: 10.2119/molmed.2013.00122. Mol Med. 2013. PMID: 24136731 Free PMC article. Clinical Trial.
Here we show in a blinded, placebo-controlled trial that 28 d of daily subcutaneous administration of ARA 290 in a group of patients with documented SNFLD significantly improves neuropathic symptoms. ...On the basis of these results and of prior studies, ARA …
Here we show in a blinded, placebo-controlled trial that 28 d of daily subcutaneous administration of ARA 290 in a group of pa …
ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response.
Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A, Cerami A, Dahan A. Swartjes M, et al. Mol Pain. 2014 Feb 16;10:13. doi: 10.1186/1744-8069-10-13. Mol Pain. 2014. PMID: 24529189 Free PMC article.
In this current study, we investigated the dose-effect relationship of the tissue protective peptide ARA 290, derived from the tertiary structure of erythropoietin, on allodynia and concurrent spinal cord microglia and astrocytes. ...
In this current study, we investigated the dose-effect relationship of the tissue protective peptide ARA 290, derived from the …
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.
Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. Heij L, et al. Mol Med. 2012 Nov 15;18(1):1430-6. doi: 10.2119/molmed.2012.00332. Mol Med. 2012. PMID: 23168581 Free PMC article. Clinical Trial.
ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing) reduces allodynia in preclinical neuropathy models. We studied the safety and efficacy of ARA 290 to redu …
ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinfla …
60 results